CAH: Crinetics Unveils Game-Changing Phase 2 Trial Results!

Introduction

Crinetics Pharmaceuticals (NASDAQ: CRNX) recently announced positive Phase 2 trial results for atumelnant, a novel treatment for Congenital Adrenal Hyperplasia (CAH) (www.gurufocus.com). While this breakthrough is focused on a rare endocrine disorder, it carries implications for Cardinal Health (NYSE: CAH) – one of the nation’s largest healthcare distributors – because any successful therapy will ultimately rely on robust distribution. Cardinal Health is a top pharmaceutical distributor and a global manufacturer/distributor of medical and laboratory products (ir.cardinalhealth.com). With over 50 years in business, operations in 30+ countries, and ~48,000 employees worldwide, Cardinal is regarded as “essential to care” in the healthcare supply chain (ir.cardinalhealth.com). The company’s scale is massive: fiscal 2023 revenue reached $205 billion (up 13% year-on-year) (www.sec.gov), solidifying Cardinal’s position among the Big Three U.S. drug wholesalers. This report provides a deep dive into Cardinal Health’s fundamentals – from its dividend and debt profile to valuation and risks – in light of industry developments like Crinetics’ game-changing trial result.

Dividend Policy & Yield

Cardinal Health has a long-standing commitment to returning cash to shareholders. The company is a Dividend Aristocrat, having increased its dividend for 29 consecutive years as of 2026 (www.kiplinger.com). Recent raises have been modest: in May 2025 the quarterly payout was nudged up to $0.5107 from $0.5056 per share (www.kiplinger.com) – roughly a 1% increase. Over fiscal 2023, Cardinal paid out a total of $1.98 per share in dividends, up just 1% from $1.96 in 2022 (www.sec.gov). This cautious growth reflects management’s conservative capital allocation even as earnings improve.

Despite the small increases, the dividend appears very secure. At the current annual rate of ~$2.04 per share, Cardinal’s yield is only about 1% (www.streetinsider.com) due to a sharply higher stock price in the past year (shares rose ~39% year-on-year) (companiesmarketcap.com). The payout ratio is low – roughly 34% of fiscal 2023 adjusted earnings (non-GAAP EPS of $5.79) (www.sec.gov). Cash flow coverage is even stronger: Cardinal generated $2.8 billion of operating cash flow in FY2023 (www.sec.gov), which is over 5 times the $525 million it paid in dividends that year (www.sec.gov). In other words, less than 20% of operating cash flow is needed to fund the dividend, leaving ample room for other uses. Management has indeed prioritized share buybacks (deploying $2.0 billion on repurchases in FY2023) over aggressive dividend hikes (www.sec.gov). Given Cardinal’s conservative payout and robust cash generation, the dividend is well-covered and poised to continue its steady (if slow) growth trajectory. Income investors can take comfort in the company’s 29-year streak of annual increases (www.kiplinger.com), even if yield alone is modest.

Leverage and Debt Maturities

Cardinal Health maintains a moderate leverage profile, underpinned by investment-grade credit ratings. As of June 30, 2023, the company’s total debt stood at $4.7 billion (including current maturities) (www.sec.gov). This is modest relative to its scale – Fitch Ratings affirms Cardinal at ‘BBB’ with a Stable outlook (www.marketscreener.com), noting that the debt/EBITDA is around 2.1× and interest coverage roughly 10.7× (stockanalysis.com). Such metrics indicate a comfortable ability to service debt. In FY2023, interest expense net of interest income was only $93 million (www.sec.gov), a trivial fraction of operating profits, reflecting strong coverage.

Maturity-wise, Cardinal’s debt is staggered and manageable. Upcoming maturities are $792 million in fiscal 2024 and $428 million in 2025, with a mid-sized $530 million note in 2026 (www.sec.gov). The largest hurdle is a $1.3 billion maturity in fiscal 2027, but thereafter obligations taper off (only $6 million in 2028 and about $1.6 billion beyond) (www.sec.gov). This schedule gives the company time to refinance or repay with internal cash flows. Notably, Cardinal’s weighted average interest rate is about 5% on its debt (www.sec.gov), and the company has been opportunistically paying down debt ($579 million repaid in FY2023) (www.sec.gov). With a BBB/Baa2 credit rating and stable outlook (www.marketscreener.com) (app.researchpool.com), Cardinal should face no issues accessing capital markets to address the 2027 bond. Overall, leverage is well-contained – a deliberate choice as Cardinal navigates an uncertain environment – providing balance sheet flexibility for strategic moves or unforeseen costs.

Coverage and Cash Flow Strength

Cardinal Health’s coverage ratios underscore its financial strength. The company’s interest coverage (EBIT divided by interest expense) is in the double-digits, reflecting how small interest costs are relative to earnings (stockanalysis.com). Even on a GAAP basis, FY2023 operating earnings of $727 million covered net interest ~7.8× (www.sec.gov) (www.sec.gov), and on an adjusted basis coverage was over 20× – a comfortable cushion. More importantly, dividend coverage by cash flow is very robust. As noted, only ~18% of operating cash flow went to dividends last year (www.sec.gov) (www.sec.gov). After funding dividends, Cardinal had roughly $2.3 billion in free cash (operating cash flow minus capital expenditures) available for other uses in FY2023 (www.sec.gov). This strong free cash flow allowed the company to buy back shares aggressively (shrinking the share count by ~6% in FY2023 alone) (www.sec.gov) while still investing in the business.

The dividend is thus well-covered by both earnings and cash flow. In FY2023, Cardinal’s non-GAAP earnings payout ratio was ~34% (www.sec.gov) (www.sec.gov), and its free cash flow payout was near 22%. Such low payout ratios, combined with the consistently positive cash generation of the distribution business, mean that Cardinal’s dividend coverage is not a concern. Even under stress scenarios – for instance, one-time legal or impairment charges that depressed GAAP profit in 2022–2023 – the company’s underlying cash flows remained ample. Cardinal’s performance through the opioid litigation (discussed below) demonstrates its resilience: it has absorbed substantial settlement payments while preserving cash flow for shareholders (www.sec.gov) (www.sec.gov). In short, coverage metrics depict a stable cash machine: Cardinal generates reliable cash that more than covers fixed charges and shareholder distributions, giving it latitude to execute strategic initiatives.

Valuation and Comps

After a strong rally in the stock, Cardinal Health’s valuation has expanded but still appears reasonable relative to peers. At around $205–$220 per share in mid-2026, CAH trades at a forward price-to-earnings (P/E) ratio of roughly 18× (stockanalysis.com). This is in line with other large healthcare distributors – for example, McKesson and Cencora (AmerisourceBergen, now renamed) also trade in the mid-teens forward P/E range. Cardinal’s trailing P/E is elevated (~31×) due to recent one-time charges (especially goodwill write-downs in its Medical segment) (stockanalysis.com) (www.sec.gov), so forward earnings are a better gauge of its normalized valuation. On a cash flow basis, the stock is more clearly attractive: the price-to-free cash flow is about 11× (stockanalysis.com), equating to a healthy ~9% free cash flow yield. Likewise, EV/EBITDA stands near 13× (stockanalysis.com), which is reasonable for a steady, low-margin business with high cash conversion.

It’s worth noting Cardinal’s price-to-sales is a mere 0.2× (stockanalysis.com) – an artifact of the distributor model (massive revenue but thin margin). This low P/S is typical for the industry and not a concern by itself; small changes in margin or volume can have big profit impact, so P/E and cash flow multiples are more meaningful. By those measures, Cardinal’s valuation seems to embed expectations of moderate growth and margin improvement. The company’s strategic moves into higher-margin specialty businesses (discussed below) could justify its multiple, which is slightly higher than the historical average. If Cardinal successfully boosts earnings in coming years (analysts project double-digit EPS growth for FY2024, for example), the forward P/E in the high teens may compress, making the stock look inexpensive on realized earnings. In summary, valuation is fair – not a screaming bargain after the recent rally, but supported by Cardinal’s cash generation and improving outlook. The stock is priced roughly on par with its big rivals, and any execution of growth initiatives (or unlocking of value via restructuring) could lead to upside beyond current multiples.

Growth Initiatives and Strategy

A key element of Cardinal’s valuation is the market’s view of its growth strategy, especially in the wake of activist involvement. In September 2022, Cardinal struck a cooperation agreement with Elliott Management, adding new directors (including an Elliott representative) and forming a Business Review Committee to scrutinize strategy and portfolio options (www.sec.gov). Under activist pressure, Cardinal has taken bold steps to reinvigorate growth, particularly by expanding in specialty healthcare. Specialty pharmaceuticals – high-cost drugs for complex diseases – have been a bright spot, growing at a 14% CAGR to over $40 billion in revenue for Cardinal in recent years (www.marketscreener.com). The company wants to capture more of the value in this segment rather than remain just a middleman.

To that end, Cardinal launched “The Specialty Alliance,” a multi-specialty management services platform, and made a string of acquisitions in the community healthcare space. In late 2025, Cardinal announced a $1.9 billion deal to acquire Solaris Health, the nation’s largest urology-focused physician management platform (www.sahmcapital.com). Solaris Health, which supports 750+ urology providers across 14 states, will join The Specialty Alliance, giving Cardinal a significant presence in urology care (www.sec.gov) (www.sec.gov). In fact, Cardinal had just completed acquisitions of Urology America, Potomac Urology, and other practice groups, so Solaris adds major scale to this Urology Alliance arm (www.sec.gov) (www.sec.gov). Cardinal will own ~75% of the Specialty Alliance after Solaris (the physicians roll over the rest) (www.sahmcapital.com). The strategic rationale is clear: accelerate specialty growth by directly partnering with provider networks in fields like urology (and previously gastroenterology, via a GI Alliance partnership) (www.sec.gov) (www.sec.gov). This should funnel distribution volume (specialty drugs, devices, lab products) through Cardinal’s channels and provide new revenue streams from management fees in these higher-margin outpatient settings (www.sahmcapital.com).

Even as Cardinal pushes into specialty care, its core Pharmaceutical distribution segment remains solid. It’s one of the top three in U.S. drug wholesaling, and continues to win new bulk contracts – about $10 billion in new customer business in FY2025, according to Fitch (www.marketscreener.com). That will boost FY2026 prospects, partially offsetting the loss of one large account (OptumRx) recently. Meanwhile, the smaller Medical Products segment (Cardinal’s own brand surgical/gloves business and medical supply distribution) has faced headwinds from cost inflation and prior missteps, but Cardinal is working to stabilize it. The company took ~$1.2 billion in goodwill impairment charges on the Medical unit in 2022–2023 (www.sec.gov) after issues like PPE oversupply and pricing pressure hurt results (www.sec.gov) (www.sec.gov). Going forward, management expects the Medical segment to recover margins as freight and commodity costs normalize (www.sec.gov) and volumes pick up. Notably, Cardinal has been simplifying this segment – for instance, it already divested the Cordis cardiovascular device business (in 2021) and addressed high-cost inventory problems. Any improvement in the Medical division would be upside, as the market currently gives it little credit (segment profit was only $111 million in FY2023) (www.sec.gov).

In summary, Cardinal’s strategy is two-pronged: protect and gradually grow the core distribution arm, and invest in adjacencies for higher margin. The Solaris deal and Specialty Alliance indicate a commitment to the latter. These moves do carry execution risk and upfront cost (Solaris’s total price including assumed rollover equity is ~$2.4 billion) (www.sahmcapital.com), but if managed well, they can deepen Cardinal’s moat in specialty drug distribution. The market appears cautiously optimistic – Cardinal’s stock performance and multiple expansion in the past year suggest investors are rewarding the proactive growth steps and greater focus brought by Elliott’s involvement.

Risks and Red Flags

Despite its strengths, Cardinal Health faces several risks and red flags that investors should monitor:

– Customer Concentration & Contract Losses: A few large clients account for outsized portions of Cardinal’s pharmaceutical distribution revenue, so losing one can sting. This was evident when OptumRx (UnitedHealth’s pharmacy unit) did not renew contracts, causing a revenue shortfall and a nearly 6% drop in Cardinal’s share price on that news (www.sahmcapital.com). Fitch notes that customer concentration is an ongoing risk – the big three distributors often have thin margins partly due to leverage from huge buyers like PBMs and hospital chains (www.marketscreener.com). If another major customer (e.g. a large retail pharmacy chain or health system) were to internalize distribution or switch to a rival, Cardinal’s volumes and bargaining power would suffer. The company’s push into specialty provider networks is partly to mitigate this risk by locking in captive demand downstream.

– Opioid Litigation & Regulatory Overhang: Cardinal, along with peers, was deeply embroiled in the U.S. opioid crisis lawsuits. In 2022 it agreed to a National Opioid Settlement, which required multi-year payouts – Cardinal has ~$5.87 billion accrued for opioid liabilities as of mid-2023 (www.sec.gov). It paid $372 million in 2023 and will owe a similar amount annually for well over a decade (www.sec.gov). These payments, while provisioned, are a cash drag and a reminder of legal risk in Cardinal’s line of work. Additionally, the company faces other suits (e.g. related to surgical gown recalls and ethylene oxide emissions from sterilization of medical products) (www.sec.gov) (www.sec.gov), though those are smaller in scale. Regulatory risks also loom: drug pricing reforms or reimbursement cuts (for example, changes to how Medicare reimburses specialty drugs) could indirectly pressure Cardinal’s margins. Any move by regulators to squeeze distributor compensation (perhaps in response to drug cost concerns) would be a negative. Fitch cites “regulatory pressures” as a factor that Cardinal must navigate alongside its growth plans (www.marketscreener.com).

– Medical Segment Struggles: Cardinal’s Medical segment has been a source of red flags in recent years. Operational mishaps – from a costly ventilator recall and PPE oversupply to general cost inflation – led to two consecutive years of goodwill impairment charges ($1.2 billion in FY2023, $2.1 billion in FY2022) (www.sec.gov). These non-cash write-downs indicate that past acquisitions (like the 2015 Cordis purchase) did not pan out as expected. The Medical unit’s profits have dwindled (only $111 million in FY2023, down 49% YoY) (www.sec.gov), and its margin fell below 1%. Management claims the worst is over – they’ve improved pricing on Cardinal-branded products and expect inflationary pressures to ease (www.sec.gov) (www.sec.gov). However, if Medical segment performance does not rebound as forecast, further write-downs or restructuring might be needed. Investors should watch for execution risk here; a failure to stabilize Medical could continue to be a drag on consolidated results and credibility.

– Competition and Disintermediation: Cardinal operates in a fiercely competitive, low-margin industry. It competes closely with McKesson and Cencora, but also faces threats from alternative models. Some drug manufacturers have tried direct distribution to large customers, bypassing wholesalers (www.sec.gov). Pharmacies and hospital systems banding together in buying coalitions (or big retailers like Amazon entering pharmacy services) could also erode the traditional distributor role. Cardinal must continue demonstrating value (in logistics efficiency, inventory management, financing, etc.) to retain its intermediary position. Pricing pressure is constant – large healthcare customers negotiate hard, and any price war among the big three could squeeze margins further (www.sec.gov). The company acknowledges that new entrants or disruptive models (e.g. online channels, specialty pharmacies owned by insurers) are a risk to both its pharma and medical segments (www.sec.gov). So far, the distribution oligopoly has held, but it’s an area to keep an eye on, especially as technology and supply chain innovations evolve.

– Strategic Uncertainty and Execution: Finally, there are open questions about Cardinal’s strategic direction as the Business Review Committee concludes its work (the Elliott cooperation agreement runs through July 2024) (www.sec.gov). One possibility is a structural change – for instance, splitting the Medical segment from the Pharmaceutical segment to unlock value. Some analysts have speculated that a spinoff or sale of the Medical unit could be beneficial if it continues underperforming. However, such moves carry execution risk and aren’t guaranteed to create value. Integrating acquisitions like Solaris Health is another execution challenge; Cardinal is effectively stepping into physician practice management, which is a new operational arena for them. If these acquisitions don’t yield the expected synergies or growth, Cardinal could face write-downs or losses on them in the future. Management’s ability to successfully diversify into higher-margin businesses while maintaining stability in the core will be critical. The recent activist-driven changes have been promising – share buybacks, cost cuts, and growth investments – but investors will be watching for tangible results (e.g. improved profit margins, higher ROIC) over the next 1–2 years to justify the new strategic course.

Conclusion and Open Questions

Cardinal Health stands today as a more dynamic company than it was a few years ago. The Phase 2 success by Crinetics – targeting a rare disease like CAH – exemplifies the kind of innovation that ultimately benefits Cardinal’s ecosystem: each new therapy that reaches market becomes product flow through Cardinal’s distribution channels or specialty networks. Cardinal’s dependable cash flows, conservative balance sheet, and shareholder-friendly capital returns underpin its investment case. Yet, the company is not without challenges or uncertainties. How effectively will Cardinal scale and integrate its Specialty Alliance acquisitions? Will the Medical segment rebound or remain a thorn in results? Can management balance growth initiatives with the ongoing cash drain of opioid settlement payments? These open questions will determine whether Cardinal’s recent stock outperformance is sustained in the years ahead.

For now, Cardinal Health appears financially strong and strategically proactive. It offers a modest dividend with a nearly 30-year track record of raises (www.kiplinger.com), and its core businesses benefit from non-cyclical demand for healthcare supplies. The unveiling of “game-changing” trial results in the biotech world is a reminder that Cardinal is an essential behind-the-scenes player in healthcare’s future – ensuring that breakthrough drugs (like a potential CAH treatment) actually reach patients. In that light, Cardinal Health’s steady execution and adaptability make it a noteworthy equity for those seeking exposure to the healthcare value chain with lower volatility than a drug developer. Investors should stay tuned as Cardinal navigates its strategic evolution, armed with a strong foundation but facing the task of delivering on the promise of its recent transformations.

Sources: Cardinal Health FY2023 10-K (www.sec.gov) (www.sec.gov) (www.sec.gov); Cardinal Health Investor Relations (ir.cardinalhealth.com) (ir.cardinalhealth.com); Cardinal Health Dividend History (www.kiplinger.com) (www.streetinsider.com); Fitch Ratings Report (www.marketscreener.com) (www.marketscreener.com); Reuters News on Solaris Acquisition (www.sahmcapital.com) (www.sahmcapital.com); Crinetics Phase 2 Press Release (www.gurufocus.com); Kiplinger analysis (www.kiplinger.com) (www.kiplinger.com).

For informational purposes only; not investment advice.